

DOCKET NO.: 296783US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

GROUP: 1635

Carsten HOPF, et al.

SERIAL NO: 10/594,213

EXAMINER: GIBBS, TERRA C.

FILED: January 19, 2007

FOR: TREATMENT OF NEURODEGENERATIVE DISEASES BY THE USE OF
LAPTM4B

RESTRICTION RESPONSE

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

In response to the Restriction Requirement dated November 15, 2007, Applicants elect, without traverse, Group I, Claims 7-10 (drawn to a method for identifying a gamma-secretase and/or a beta-secretase modulator comprising a) identifying a LAPTM4B-interacting molecule and b) determining whether the LAPTM4B-interacting molecule is capable of modulating gamma-secretase and/or beta-secretase activity), for examination.

Remarks/Arguments begin on page 2 of this paper.